Supplementary material from "Serological inference of past primary and secondary dengue infection: implications for vaccination"

Owing to the finding that Dengvaxia^® (the only licensed dengue vaccine to date) increases the risk of severe illness among seronegative recipients, the World Health Organization has recommended screening individuals for the serostatus prior to vaccination. To decide whether and how to carry out screening, it is necessary to estimate the transmission intensity of dengue and to understand the performance of the screening method. In this study, we inferred the annual force of infection (FOI; a measurement of transmission intensity) of dengue virus in three locations in Vietnam: An Giang (FOI = 0.04 for the below 10 years age group and FOI = 0.20 for the above 10 years age group), Ho Chi Minh City (FOI = 0.12) and Quang Ngai (FOI = 0.05). In addition, we show that using a quantitative approach to IgG (immunoglobulin G) levels (measured by indirect enzyme-linked immunosorbent assays (ELISAs)) can help to distinguish individuals with primary exposures (primary-seropositive) from those with secondary exposures (secondary-seropositive). We found that primary-seropositive individuals—the main targets of the vaccine—tend to have a lower IgG level, and thus, they have a higher chance of being misclassified as seronegative, as compared with secondary-seropositive cases. However, screening performance can be improved by incorporating patient age and transmission intensity into the interpretation of IgG levels.